rac-(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetic acid salt

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: rac-(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetic acid salt
• 英文别名: (±)-(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetic acid salt；rac-(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluoro-phenyl)-2'-(2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetate；(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluoro-phenyl)-2'-(2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetic acid；(2'R,3R,3'S,5'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxylic acid;2,2,2-trifluoroacetic acid
• 化学式: C₂HF₃O₂*C₂₃H₂₃Cl₂FN₂O₃
• 分子量: 579.376
• InChiKey: AABBNXHBQNUEQW-ZPITZRBNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  38
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  rac-(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetic acid salt 在 盐酸 、 二氧化碳 、 N,N-二异丙基乙胺 、 二苯基次膦酰氯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 20.0~35.0 ℃ 、10.0 MPa 条件下， 反应 74.13h， 生成 (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid [4-(2-hydroxyethoxy)-2-methoxyphenyl]amide
  参考文献：
  名称：

  Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

  摘要：

  The field of small-molecule inhibitors of protein-protein interactions is rapidly advancing and the specific area of inhibitors of the p53/MDM2 interaction is a prime example. Several groups have published on this topic and multiple compounds are in various stages of clinical development. Building on the strength of the discovery of RG7112, a Nutlin imidazoline-based compound, and RG7388, a pyrrolidine-based compound, we have developed additional scaffolds that provide opportunities for future development. Here, we report the discovery and optimization of a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitors, culminating in RO8994. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.05.072
• 作为产物：
  描述：

  3,3-二甲基丁醛 在 silver fluoride 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 38.0h， 生成 rac-(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid trifluoroacetic acid salt
  参考文献：
  名称：

  SPIROINDOLINONE PYRROLIDINES

  摘要：

  提供了以下式中的化合物，其中X、Y和R1至R8如本文所述，以及其对映体、药用可接受的盐和酯。这些化合物可用作抗癌药物。

  公开号：

  US20110130398A1

文献信息

• Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors
  作者：Yujun Zhao、Liu Liu、Wei Sun、Jianfeng Lu、Donna McEachern、Xiaoqin, Li、Shanghai Yu、Denzil Bernard、Philippe Ochsenbein、Vincent Ferey、Jean-Christophe Carry、Jeffrey R. Deschamps、Duxin Sun、Shaomeng Wang

  DOI：10.1021/ja3125417

  日期：2013.5.15

  which affords four diastereomers from a single compound. Our biochemical binding data showed that the stereochemistry in this class of compounds has a major effect on their binding affinities to MDM2, with >100-fold difference between the most potent and the least potent stereoisomers. Our study has led to the identification of a set of highly potent MDM2 inhibitors with a stereochemistry that is different

  阻断 MDM2-p53 蛋白-蛋白相互作用的小分子抑制剂（MDM2 抑制剂）作为一种新的癌症治疗策略正受到强烈追捧。我们之前发表了一系列含有螺环吲哚的化合物作为一类新的 MDM2 小分子抑制剂。我们在此报告了这些螺吲哚中的一些的可逆开环环化反应，该反应从单个化合物提供四种非对映异构体。我们的生化结合数据表明，这类化合物的立体化学对其与 MDM2 的结合亲和力有主要影响，最强和最弱立体异构体之间的差异大于 100 倍。我们的研究已经确定了一组高效的 MDM2 抑制剂，其立体化学不同于我们之前报道的化合物。
• Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
  申请人：Chu Xin-Jie

  公开号：US20120071499A1

  公开（公告）日：2012-03-22

  There are provided compounds of the formula wherein X, Y, R 1 , R 1′ , R 2 , R 2′ , R 3 , R 4 , R 5 and R 6 are as described herein and enantiomers or a pharmaceutically acceptable salt or ester thereof. The compounds are useful as anticancer agents.

  提供了具有以下结构的化合物，其中X、Y、R1、R1'、R2、R2'、R3、R4、R5和R6如本文所述，其对映体或药用可接受的盐或酯。这些化合物可用作抗癌剂。
• Spiroindolinone pyrrolidines
  申请人：Hoffman-La Roche Inc.

  公开号：US08088815B2

  公开（公告）日：2012-01-03

  There are provided compounds of the formula wherein X, Y and R1 to R8 are described herein along with the enantiomers, pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了具有以下式子的化合物，其中X、Y和R1到R8的描述在此提供，还提供它们的对映体、药学上可接受的盐和酯。这些化合物可用作抗癌剂。
• Synthesis of a Spiroindolinone Pyrrolidinecarboxamide MDM2 Antagonist
  作者：Lianhe Shu、Zizhong Li、Chen Gu、Dan Fishlock

  DOI：10.1021/op3003213

  日期：2013.2.15

  A practical synthesis of a spiroindolinone pyrrolidinecarboxamide MDM2 antagonist 2 is reported. Cycloaddition of dipolarophile 3 with imine 30 afforded a complex mixture of diastereomers that were isomerized to the desired stereoisomer 31 by heating the mixture in the presence of DBU. After hydrolysis, the resulting product was resolved with a chiral amine to give an enantiopure acid which was converted to the target product 2. The process has been scaled up to a multihundred-gram scale. In addition, an asymmetric synthesis of 31 catalyzed by AgOAc and a chiral phosphine ligand was developed to give enantiomerically enriched 31, which was also converted to enantiopure 2.
• US8088815B2
  申请人：——

  公开号：US8088815B2

  公开（公告）日：2012-01-03